C-Cyclopropyl-C-(3,4-dichloro-phenyl)-methylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: C-Cyclopropyl-C-(3,4-dichloro-phenyl)-methylamine
• 英文别名: Cyclopropyl(3,4-dichlorophenyl)methanamine；cyclopropyl-(3,4-dichlorophenyl)methanamine
• 化学式: C₁₀H₁₁Cl₂N
• 分子量: 216.11
• InChiKey: BCQBDKWNINNFAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  C-Cyclopropyl-C-(3,4-dichloro-phenyl)-methylamine 在 盐酸 作用下， 以 异丙醇 为溶剂， 生成
  参考文献：
  名称：

  [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  [FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2

  摘要：

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。

  公开号：

  WO2006015986A1
• 作为产物：
  描述：

  cyclopropyl(3,4-dichlorophenyl)methanone oxime 在 溶剂黄146 、 锌 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 18.0h， 生成 C-Cyclopropyl-C-(3,4-dichloro-phenyl)-methylamine
  参考文献：
  名称：

  [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  [FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2

  摘要：

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。

  公开号：

  WO2006015986A1

文献信息

• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200102288A1

  公开（公告）日：2020-04-02

  Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了抑制WDR5和相关蛋白质-蛋白质相互作用的亚氨基-氮杂环-苯甲酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和状况的方法。
• WDR5 inhibitors and modulators
  申请人：Vanderbilt University

  公开号：US10844044B2

  公开（公告）日：2020-11-24

  Described are imino-azacycle-benzamide compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了抑制 WDR5 和相关蛋白-蛋白相互作用的亚氨基氮杂环苯甲酰胺化合物、包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和病症的方法。
• 2-Mercaptoimidazoles, a new class of potent CCR2 antagonists
  作者：Guy Van Lommen、Julien Doyon、Erwin Coesemans、Staf Boeckx、Marina Cools、Mieke Buntinx、Bart Hermans、Jean VanWauwe

  DOI：10.1016/j.bmcl.2004.11.064

  日期：2005.2

  We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca-flux below 0.01 muM. (C) 2004 Elsevier Ltd. All rights reserved.
• Mercaptoimidazoles as ccr2 receptor antagonists
  申请人：Lommen Rosalia Eugeen Guy

  公开号：US20070167456A1

  公开（公告）日：2007-07-19

  The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 represents hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkyloxyC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, aryl or heteroaryl; each R 2 independently represents halo, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C 1-4 alkyl)amino, nitro, aryl or aryloxy; R 3 represents cyano, C(═O)—O—R 5 , C(═O)—NR 6a R 6b or C(═O)—R 7 ; or a cyclic ring system; R 4 represents hydrogen or C 1-6 alkyl; n is 1, 2, 3, 4 or 5; R 10 represents hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, arylcarbonyl, heteroarylcarbonyl, —C(═O)—NH—R 5 , —C(═S)—NH—R 5 or —S(═O) 2 —R 5 . The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.
• MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  申请人：VAN LOMMEN Guy Rosalia Eugeen

  公开号：US20090192206A1

  公开（公告）日：2009-07-30

  The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 represents hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkyloxyC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, aryl or heteroaryl; each R 2 independently represents halo, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C 1-4 alkyl)amino, nitro, aryl or aryloxy; R 3 represents hydrogen, cyano, C 1-6 alkyl optionally substituted with hydroxy or C 1-6 alkyloxy, C(═O)—O—R 6 , C(═O)—NR 7a R 7b , C(═S)—NR 7a R 7b , S(═O) 2 —NR 7a R 7b or C(═O)—R 8 ; R 4 represents hydrogen, cyano, C 1-6 alkyl optionally substituted with hydroxy or C 1-6 alkyloxy, C(═O)—O—R 6 , C(═O)—NR 7a R 7b , C(═S)—NR 7a R 7b , S(═O) 2 —NR 7a R 7b or C(═O)—R 8 ; or R 3 and R 4 taken together may form a bivalent radical of formula —C(═O)—NH—NH—C(═O)—; n is 1, 2, 3, 4 or 5; provided that at least one of R 3 or R 4 is other than hydrogen; and that if R 3 represents C(═O)—OH, C(═O)—O—C 1-6 alkyl or C(═O)—O—C 2-6 alkenyl, then R 4 is other than hydrogen; and that if R 3 represents CH 2 OH and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen; and that if R 3 represents C(═O)—NH—C 1-4 alkyl-NH 2 and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen; and that if R 3 represents and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (1) and pharmaceutical compositions comprising them.